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Phase II Trial of Vinflunine in Relapsed Small Cell Lung
Cancer
David R. Spigel, MD,*† John D. Hainsworth, MD,*† Cassie M. Lane, MS,* Bobby Clark, PhD,*
Howard A. Burris, III, MD,*† and F. Anthony Greco, MD*†
Background: Vinflunine is a new microtubule inhibitor with pre-
clinical activity in small cell lung cancer (SCLC). In this phase II
trial, we evaluated vinflunine in patients with relapse-sensitive and
refractory SCLC.
Methods: This trial aimed to achieve a 20% objective response rate
(ORR) in platinum-sensitive patients. Patients with Eastern Coop-
erative Oncology Group performance status 0 to 2 and measurable
disease received vinflunine (320 mg/m2 IV) every 21 days (6
cycles; response evaluation every 6 weeks).
Results: Patient characteristics (N  51): median age 63 years
(range, 37–85 years); male, 55%; Eastern Cooperative Oncology
Group performance status 2, 16%; relapse-sensitive SCLC, 53%.
The overall ORR was 19.6% (95% confidence interval [CI] 10–
33%). Twelve (23.5%) patients had stable disease; 18 (35.3%)
patients had progressive disease. Among relapse-sensitive patients,
ORR was 22.2% (95% CI 9–42%). Among relapse-refractory pa-
tients, ORR was 16.7% (95% CI 5–37%). Median follow-up was 15
months (range, 12–18 months); median progression-free survival
(PFS) was 1.6 months (95% CI 1.3–3.9 months); median overall
survival (OS) was 4.9 months (95% CI 3.2–6.5 months). Among
relapse-sensitive patients, PFS and OS were 1.6 and 4.9 months,
respectively. Among relapsed-refractory patients, PFS and OS were
1.4 and 4.0 months, respectively. In general, vinflunine was well
tolerated, although neutropenia was a notable toxicity. Grade 3/4
toxicities (5%): neutropenia (32%), arthralgia/myalgia (16%), fa-
tigue (16%), hyponatremia (12%), leukopenia (12%), nausea/vom-
iting (12%), constipation (6%), and thrombocytopenia (6%). The
rates of toxicities were relatively well balanced among relapse-
sensitive and refractory patients; one patient died of sepsis that was
possibly treatment related.
Conclusions: Vinflunine has activity in relapsed SCLC, including
refractory relapsed patients. Neutropenia was common but associ-
ated with rare febrile episodes. Additional study in relapse-refrac-
tory SCLC is indicated.
Key Words: Vinflunine, Relapse, Single-agent therapy, Small-cell
lung cancer.
(J Thorac Oncol. 2010;5: 874–878)
Majority of patients diagnosed with small cell lung cancer(SCLC) will relapse and die of disease despite achiev-
ing high response rates with combination first-line therapy.1
The only Food and Drug Administration-approved therapy
for patients with relapse-sensitive SCLC (disease that re-
sponded to first-line therapy but subsequently progressed at
least 60–90 days after treatment) is topotecan. This approval
was based on improved symptoms seen in a randomized trial
comparing topotecan with cyclophosphamide, doxorubicin,
and vincristine in patients with relapse-sensitive SCLC.2 An
oral formulation was recently approved based on equivalence
to the intravenous formulation and benefit over supportive care
alone.3,4 Despite these approvals, topotecan is associated with a
modest response rate (range, 7–24%) and survival (5.8–8.8
months). There are no approved therapies for patients with
relapse-refractory SCLC (disease that progresses within 60–90
days of first-line therapy). Newer therapies are needed.
Vinflunine is a new vinca alkaloid microtubule inhibi-
tor that causes cell cycle arrest and apoptosis.5,6 Vinflunine
demonstrated pronounced activity in multiple cancer cell
lines, including small cell lung cancer.7–10 This early efficacy
prompted clinical investigation of single agent vinflunine in
multiple solid tumor settings, including non-small cell lung
cancer and mesothelioma.11–16 Herein, we report on a multi-
center phase II trial where vinflunine was administered to
patients with relapse-sensitive and refractory SCLC.
PATIENTS AND METHODS
This trial was initiated in March 2006. Participating
centers included the Sarah Cannon Research Institute and
selected sites from the Sarah Cannon Oncology Research
Consortium, a national community-based research network.
Patients
Patients with SCLC who had progressed after one
previous chemotherapy or chemotherapy/radiation regimen
were enrolled. Patients who had progressive tumor or relapse
more than 3 months since the end of the last cycle of
chemotherapy were considered “relapse-sensitive” patients.
Patients who had progressive tumor or relapse within 3
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months of chemotherapy ending were considered “relapse-
refractory” patients. Patients had measurable disease per
Response Evaluation Criteria in Solid Tumors (RECIST).17
Other eligibility criteria included age 18 years; presence of
untreated brain metastases, Eastern Cooperative Oncology
Group (ECOG) performance status (PS) 0 to 2; and adequate
organ function (defined as absolute neutrophil count [ANC]
1.0  109/L, platelet count 100  109/L, serum bilirubin
1.25  the upper limit of normal serum aspartate transam-
inase 5  the upper limit of normal, and serum creatinine
2.0 mg/dL).
Exclusion criteria included pregnancy or lactation; clin-
ically significant cardiovascular disease; or other active ma-
lignancy. All patients provided written informed consent
before enrollment.
Pretreatment Evaluation
Before treatment, patients were evaluated by history,
physical examination, and laboratory testing. Baseline tumor
staging was performed using computed tomography (CT) of
the chest, abdomen, and pelvis; CT or magnetic resonance
imaging of the brain; and bone scan or positron emission
tomography.
Treatment Plan
All patients received vinflunine 320 mg/m2 every 21
days as a 15- to 20-minute infusion (reconstituted in 100 mL
of 0.9% normal saline) (Figure 1). Additional support in-
cluded hydration, fiber supplements, and laxatives. Patients
were restaged with CT scans every 2 cycles or 6 weeks (per
RECIST). If there was no evidence of disease progression or
significant toxicity, patients received up to 6 cycles.
Dose modifications were based on ANC and platelet
counts on day 1 of each cycle; and doses were not increased
once modified. No adjustments were required if the ANC was
1.0  109/L and platelet count 100  109/L. If the ANC
was 1.0  109/L or platelets 100  109/L, chemotherapy
was held until counts recovered to baseline parameters. Pa-
tients requiring hospitalization for neutropenia and fever had
dose reductions (first episode: 280 mg/m2, second episode:
250 mg/m2). Chemotherapy was also reduced for severe
nonhematologic toxicity.
Toxicity assessments were made according to the com-
mon terminology criteria for adverse events (version 3.0) of
the National Cancer Institute. Cytokines were not adminis-
tered with the first course of treatment; however, prophylactic
granulocyte colony-stimulating factor for patients experienc-
ing febrile neutropenia was permitted at the discretion of the
treating physician and was not to substitute for mandated
dose reductions.
This trial was approved by the institutional review
boards of all participating institutions and was conducted in
accordance with Food and Drug Administration Good Clin-
ical Practices and local, ethical, and legal requirements. The
Sarah Cannon Research Institute designed and coordinated
the trial and was responsible for all aspects of data collection
and analysis. Vinflunine was provided by Bristol-Myers
Squibb (New York, NY).
TABLE 1. Patient Characteristics (n  51)
Characteristic No. of Patients (%)














Lymph nodes 27 (53)
Pleural effusion 6 (12)
Central nervous system 4 (8)
Other 15 (29)
Site of treatment
Tennessee oncology 14 (27)
Network sites 37 (73)
ECOG, Eastern Cooperative Oncology Group; PS, performance status.
FIGURE 1. Treatment plan.
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Definition of Response
All patients were evaluated for response by RECIST
criteria. The final response category assigned represented the
best response obtained during treatment.
Statistical Methods
The primary objective of this phase II trial was to assess
the overall objective response rate (ORR) in patients with
relapsed SCLC treated with single agent vinflunine. If the
administration of intravenous vinflunine failed to provide
efficacy that was at least comparable with the average expe-
rience of single agent topotecan (i.e., 20%) in relapse-sensi-
FIGURE 2. Progression-free sur-
vival and overall survival.




(n  51) No. of
Patients (%)
Refractory
(n  24) No. of
Patients (%)
Sensitive
(n  27) No. of
Patients (%)
CR 0 0 0
PR 10 (19.6) 4 (16.7) 6 (22.2)
SD 12 (23.5) 6 (25) 6 (22.2)
PD 18 (35.3) 9 (37.5) 9 (33.3)
UE 11 (21.6) 5 (20.8) 6 (22.2)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; UE, unevaluable.
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tive SCLC, then there would not be further interest in
developing the proposed regimen in this population. Sec-
ondary end points included assessments of toxicity, pro-
gression-free survival (PFS), overall survival (OS), and
duration of response.
It was hypothesized that vinflunine would result in an
objective response of 20% in the intent-to-treat population.
This trial employed a Simon optimal design. For a total of 41
subjects, 21 would be accrued during stage 1, and 20 during
stage 2. The alpha level of the design was 0.05; and the power
was 0.9.
Efficacy outcomes were based on intent-to-treat analy-
ses. PFS was defined as the interval between the start date of
treatment and the date of occurrence of progressive disease or
death. OS was measured from the date of study entry until the
date of death. Survival curves were constructed using the
method of Kaplan and Meier.18
RESULTS
Patient Characteristics
Fifty-one patients were enrolled from March 2006 to
April 2007, 27% from our Nashville, TN, site and 67% from
other consortium sites. Baseline characteristics for all patients
are described in Table 1. The median age was 63 years
(range, 37–85 years). Twenty-eight (55%) patients were men
and 23 patients were women. ECOG PS was 0 in 13 (25%)
patients, 1 in 30 (59%) patients, and 2 in 8 (16%) patients.
Twenty-four (47%) patients had relapse-refractory SCLC and
27 patients had sensitive disease. Metastatic sites included
liver (51%), lymph nodes (53%), and bone (35%), among
other sites.
Treatment Received
The median follow-up is 15 months (range, 12–18
months). Eleven (22%) patients were not evaluable for a
response because of treatment compliance (1 patient), clinical
progression without documented imaging (3 patients), poor
clinical response/worsening symptoms (1 patient), physician
discretion (1 patient) death due to disease (3 patients), and
treatment-related toxicity (pain and constipation in 1 patient
and sepsis and hematologic toxicity in 1 patient). All these
patients were included in the efficacy analyses.
Response
The overall ORR was 19.6% (10 of 51 patients) (95%
confidence interval [CI] 10–33%) (Table 2). There were no
complete responses. Twelve (23.5%) patients had stable dis-
ease and 18 (35.3%) patients had progressive disease. The
median response duration was 2.7 months (95% CI 1.9–
3.9%). Among relapse-sensitive patients, the ORR was
22.2% (95% CI 9–42%). Among relapse-refractory patients,
the ORR was 16.7% (95% CI 5–37%).
Progression-Free Survival and Survival
The median PFS was 1.6 months (95% CI 1.3–3.9
months) (Figure 2A). The median OS was 4.9 months (95%
CI 3.2–6.5 months) (Figure 2B). One-year OS was 16% (95%
CI 8–28%). Among relapse-sensitive patients, PFS, median
OS, and 1-year OS were 1.6 months, 4.9 months, and 7%,
respectively. Among relapse-refractory patients PFS, median
OS, and 1-year OS were 1.4 months, 4.0 months, and 27%,
respectively.
Treatment-Related Toxicity
Treatment-related toxicity is summarized in Table 3. In
general, vinflunine was well tolerated although neutropenia
was a notable toxicity. Neutropenic fever occurred in 1 (2%)
patient overall. The most common (3%) grade 3/4 toxicities
were neutropenia (32%), leukopenia (12%), thrombocytope-
nia (6%), anemia (4%), fatigue (16%), nausea/vomiting
(12%), arthralgia/myalgia (16%), dyspnea (4%), hyponatre-
TABLE 3. Grade 3/4 Treatment-Related Toxicity in 4% of Patients (n  51; 149 Treatment
Cycles)
Toxicity




(n  27) Total (n  51)
G3 G4 G3 G4 G3 G4
Hematologic
Hemoglobin 0 1 (4) 1 (4) 0 1 (2) 1 (2)
Leukocytes 2 (8) 1 (4) 2 (7) 1 (4) 4 (8) 2 (4)
Neutrophils 3 (13) 5 (21) 3 (11) 5 (19) 6 (12) 10 (20)
Platelets 2 (8) 1 (4) 2 (7) 0 2 (4) 1 (2)
Neutropenic fever 0 0 1 (4) 0 1 (2) 0
Nonhematologic
Fatigue 4 (17) 0 4 (15) 0 8 (16) 0
Nausea/vomiting 4 (17) 0 2 (7) 0 6 (12) 0
Arthralgia/myalgia 4 (17) 0 4 (15) 0 8 (16) 0
Dyspnea 2 (8) 0 0 0 2 (4) 0
Hyponatremia 2 (8) 0 1 (4) 3 (11) 3 (6) 3 (6)
Constipation 2 (8) 0 1 (4) 0 2 (6) 0
Anorexia 1 (4) 0 1 (4) 0 2 (4) 0
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mia (12%), constipation (6%), and anorexia (4%). The rates
of toxicities were relatively well balanced among relapse-
sensitive and refractory patients. Fifty-three percent of pa-
tients experienced grade 1 or 2 constipation. One patient died
of sepsis that was possibly treatment related.
DISCUSSION
Fifty percent of patients diagnosed with SCLC will
relapse within 4 to 6 months of first-line therapy. There are
limited treatment options for these patients, half of whom will
not survive the first year.1,3,19 Topotecan is commonly used in
the relapsed setting but is associated with severe neutropenia
and modest efficacy.2 Newer therapies are needed for these
patients.
Vinflunine is a novel microtubule inhibitor that has
demonstrated antitumor activity in multiple cell lines, includ-
ing SCLC. Preliminary clinical activity has been observed in
patients with breast, genitourinary, and lung cancers.11–16,20
The 21-day dosing is relatively more convenient than 5-day
dosing with topotecan and is well tolerated and safe.
In this phase II study, vinflunine resulted in partial
responses in 20% of patients with relapsed SCLC. This rate is
equivalent to rates observed with topotecan in prospective
clinical trials.2–4 Notably, vinflunine also achieved partial
responses in 17% of patients with relapse-refractory SCLC, a
rate that is substantially higher than expected in this patient
subset. Unfortunately, the overall response rate did not trans-
late into an extended survival in the overall population. In
general, the toxicity was expected and relatively modest
overall, although severe neutropenia was observed in one-
third of patients and may have contributed to one patient
death due to sepsis.
This trial is limited by its single cohort design and small
subsets of relapsed patients. The confidence interval is wide
for the response rate in the refractory subset and may be
substantially different in a larger prospective trial. In addi-
tion, most of the patients enrolled in this trial had an ECOG
PS of 0 or 1, despite allowing for a PS of 2. This may not best
reflect what many of the sicker patients’ oncologists encoun-
ter in the relapsed setting and potentially overestimates the
treatment benefit for other patients.
In summary, vinflunine is a new vinca alkaloid that
seems to be well tolerated as a single agent in patients with
relapsed SCLC. In this multicenter community-based trial,
vinflunine seemed to have activity in both relapse-sensitive
and refractory patients, with acceptable toxicity. Additional
study in relapse-refractory SCLC is warranted. Ongoing trials
in other tumor settings with vinflunine may help to further
characterize its overall safety and potential future role in
clinical care.
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